Journal
ANTIVIRAL THERAPY
Volume 18, Issue 2, Pages 141-147Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP2402
Keywords
-
Categories
Funding
- NIH [R01AT006842, R56/R01-AI078881, P20-GM103452]
- US Department of Energy
- Agence Nationale pour la Recherche contre le SIDA et les hepatites virales (ANRS)
- ANRS
- INSERM
- Fondation pour la Recherche Medicale
- National Center for Complementary & Integrative Health [R01AT006842] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078881, R56AI078881] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103452] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Silymarin, an extract of milk thistle seeds, and silymarinderived compounds have been considered hepatoprotective since the plant was first described in ancient times. Hepatoprotection is defined as several non-mutually exclusive biological activities including antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for beneficial effects in humans has been equivocal. This review will summarize the current state of knowledge on silymarin in the context of HCV infection. The information was collated from a recent workshop on silibinin in Germany.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available